Why Is AUNA Stock Up Today After a 15% Earnings Crash?

TL;DR

• AUNA fell as much as 15.13% intraday on Wednesday, to $4.60, after Auna S.A.'s second-quarter results missed profit estimates. It closed at $5.43, up 0.18% from Tuesday's $5.42, after also trading as high as $5.64 the same session.
• Revenue beat: S/1,238 million (about $363 million), up 13% year over year on a reported basis. Adjusted EBITDA fell to S/227 million from S/241 million, and the margin dropped to 18.4% from 22.1%.
• Adjusted net income more than halved, to S/40 million from S/89 million, and reported net income fell to S/33 million from S/84 million.
• Management called the margin hit temporary and reaffirmed full-year guidance: revenue growth near 12% FX-neutral, Adjusted EBITDA growth toward the low end of a 10-14% FX-neutral range.
• On the company's own numbers, first-half 2026 Adjusted EBITDA is already down 4% year over year, which means the second half has a lot of ground to make up to hit even the bottom of that range.

The Board

Auna round-tripped a 15% earnings drop in a single session. The guidance math is the part that didn't round-trip.

Why Is AUNA Stock Up Today?

It barely is. AUNA closed Wednesday at $5.43, up 0.18% from Tuesday's $5.42, but that flat-looking number hides a violent session: shares gapped down as much as 13.65% in premarket trading to $4.68, fell further to an intraday low of $4.60 (down 15.13%), then reversed hard enough to trade as high as $5.64 before settling almost exactly where they started, per stockanalysis.com and cross-checked against Google Finance. Auna S.A. is a Lima, Peru-based hospital and health-insurance operator with facilities across Peru, Mexico and Colombia, and it reported second-quarter 2026 results before Wednesday's open.

Auna doesn't get much English-language financial press. It trades on the NYSE, but the coverage that exists is mostly syndicated wire summaries and data aggregators, several of which quote a Wall Street consensus EPS figure for this quarter that doesn't reconcile against the miss percentage those same pieces report. I'm not using that number here. What follows uses only what's in the company's own Form 6-K, filed with the SEC on August 18.

What Actually Happened to the Numbers

Consolidated revenue was S/1,238 million, up 13% year over year on a reported basis and 9% on an FX-neutral basis, ahead of the top-line estimates most trackers had out. That's the headline the stock did not reward.

Adjusted EBITDA fell to S/227 million from S/241 million a year earlier, a decline of 6% reported (9% FX-neutral), and the margin compressed to 18.4% from 22.1%. Reported net income fell to S/33 million from S/84 million. Adjusted net income, which strips out one-off items, fell to S/40 million from S/89 million, working out to adjusted earnings per share of S/0.50 on 74.24 million weighted-average shares.

Management's explanation, from the same filing: "temporary margin pressure in Mexico and Colombia, as well as pharmacy and payroll costs, along with the impact of accepted penalties primarily related to billing matters." Free cash flow, for what it's worth, actually improved a lot: roughly S/400 million for the first half of the year, up 181% from a year earlier, on better working-capital management.

Where the Margin Actually Went

Auna reports four segments, and they didn't compress evenly. Mexico was the strongest performer by margin, at 25.9% on S/300 million of revenue. Oncosalud, the Peru insurance arm, ran 21.0% on S/317 million. Colombia came in at 13.1% on S/427 million, its largest revenue segment. Peru's hospital and clinic business, separate from the Oncosalud insurance line, was the weak spot at 11.7% on S/296 million, the lowest margin of the four. A holding and elimination line subtracts roughly S/103 million of revenue and S/8 million of EBITDA for intersegment accounting, which is what gets the segment totals down to the consolidated S/1,238 million and S/227 million.

Colombia carrying the most revenue at the second-weakest margin, and Peru's core hospital business sitting at the bottom of the group, is a different story than "margins fell." It's specific: two of four segments are underperforming their own history, and management is attributing both to costs it says won't recur.

The Guidance Math That Actually Matters

Auna reaffirmed its full-year 2026 outlook Wednesday: revenue growth near 12% FX-neutral (a 10-14% range), and Adjusted EBITDA growth "toward the low end of that range." I want to be upfront that the arithmetic below is mine, done against figures the company reported rather than a target it published itself. It also mixes an FX-neutral growth rate with reported soles, so treat it as an approximation rather than a precise reconciliation.

Full-year 2025 Adjusted EBITDA was S/917 million. Ten percent growth off that base, the low end of guidance, points to a full-year 2026 target near S/1,009 million. First-half 2026 Adjusted EBITDA, per Wednesday's release, was S/444 million, down from S/464 million in the first half of 2025. That leaves roughly S/565 million needed from the second half of this year. Second-half 2025 delivered S/453 million. Getting from S/453 million to S/565 million is close to 25% growth, in a half where the first half of the year just went the other way.

I'm not saying it can't happen: Colombia and Peru's insurance arm are both running double-digit margins already, and management has a specific, named list of costs it says are temporary. But a company that just posted its second straight quarter of shrinking Adjusted EBITDA needs that list to actually be temporary, on a timeline of months, not quarters.

Leverage Is Moving the Wrong Way, Too

Auna's leverage ratio stood at 3.6x at the end of June, against net debt of S/3,252 million. The company's own target is below 3.0x. That gap was already there before Wednesday's print; nothing in the quarter closed it, and a business generating less EBITDA than the year before is, all else equal, a business getting further from a leverage target measured against EBITDA. The 181% jump in free cash flow is the one clean offsetting data point, since it's cash that can actually pay debt down rather than a ratio moving on the denominator.

Has This Happened Before?

Once, more mildly. Auna's first-quarter 2026 results in May also missed profit estimates, with the Adjusted EBITDA margin also compressed sharply from the year-ago quarter. The stock fell about 4% after hours that time, not 15%. Two consecutive quarters of margin compression, both blamed on cost items rather than demand, is a pattern worth naming rather than two unrelated misses. If a third quarter in November shows the same shape, "temporary" stops being an explanation and starts being a label.

Is AUNA a Buy Right Now?

I don't think Wednesday's close price tells you much, given how far the stock traveled to get there. The case for owning it: revenue growth is real and running ahead of guidance's own midpoint, free cash flow just had its best half in years, Mexico and Oncosalud both carry margins in the low-to-mid 20s, and this is the only NYSE-listed pure play on Latin American private healthcare, a market most US-based readers have no other way to access.

The case against it: leverage is above the company's own target while EBITDA is shrinking, not growing, guidance now requires a second-half acceleration the company hasn't demonstrated it can deliver, and a 74-million-share float just proved it can swing nearly 20 percentage points in a single session on one earnings report. That's not a stock where you can assume the next print behaves like a normal-sized company's quarter. I'd want to see one quarter where the margin story actually turns before I treat "temporary" as a fact rather than as what management is currently asking investors to believe.

The Options Angle

No live, reliably sourced options chain for AUNA was available this session. It's a $400-million-market-cap foreign private issuer with a thin float, and even where a chain nominally exists for a name this size, the quoted spreads are usually wide enough that the quote itself isn't a tradeable price. I'm passing on any structure rather than pricing against a number I can't verify.

Trade log

#	Stance	Structure	Strikes and expiry	Cost or credit	Spot at writing	Implied move	Conviction	Breakeven
1	Pass	Long common, chasing the close	n/a, shares	n/a	$5.43	n/a	4/10	needs a fresh catalyst beyond today's round trip
2	Pass	Any directional options structure	Not sourced	Not sourced	$5.43	Not sourced	3/10	N/A

Both rows are logged in the Track Record ledger and will be graded against Auna's next reporting date, expected around November 2026.

For readers tracking a similar dynamic elsewhere this month, Fabrinet's fiscal Q4 print did the mirror version of this: a clean beat that fell harder than two prior misses, because the market focused on free cash flow and a debt-funded capex ramp rather than the headline. Both are cases where the number that actually moved the stock wasn't the one in the press release's first paragraph. This week's full calendar is in the week-ahead hub.

The One-Line Read

AUNA fell 15% intraday and finished up 0.18%. What matters more than either number: this year's guidance now needs a second-half EBITDA swing Auna hasn't shown it can produce.